Nothing Special   »   [go: up one dir, main page]

PL2723769T5 - Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny - Google Patents

Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny

Info

Publication number
PL2723769T5
PL2723769T5 PL12729968.3T PL12729968T PL2723769T5 PL 2723769 T5 PL2723769 T5 PL 2723769T5 PL 12729968 T PL12729968 T PL 12729968T PL 2723769 T5 PL2723769 T5 PL 2723769T5
Authority
PL
Poland
Prior art keywords
predicting
techniques
detecting
variable domains
single variable
Prior art date
Application number
PL12729968.3T
Other languages
English (en)
Other versions
PL2723769T3 (pl
Inventor
Judith Baumeister
Marie-Paule Lucienne Armanda Bouche
Carlo Boutton
Marie-Ange Buyse
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2723769(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PL2723769T3 publication Critical patent/PL2723769T3/pl
Publication of PL2723769T5 publication Critical patent/PL2723769T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PL12729968.3T 2011-06-23 2012-06-25 Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny PL2723769T5 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
US201161500360P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins
PCT/EP2012/062251 WO2012175741A2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (2)

Publication Number Publication Date
PL2723769T3 PL2723769T3 (pl) 2017-07-31
PL2723769T5 true PL2723769T5 (pl) 2022-10-17

Family

ID=47423024

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12729968.3T PL2723769T5 (pl) 2011-06-23 2012-06-25 Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny

Country Status (22)

Country Link
US (11) US20180009888A9 (pl)
EP (1) EP2723769B2 (pl)
JP (6) JP6258199B2 (pl)
KR (7) KR20220114104A (pl)
CN (5) CN108663504B (pl)
AU (7) AU2012273929B2 (pl)
BR (3) BR122018012485B1 (pl)
CA (3) CA3141978A1 (pl)
DK (1) DK2723769T4 (pl)
ES (1) ES2622006T5 (pl)
HU (1) HUE031828T2 (pl)
IL (4) IL229503B (pl)
IN (1) IN2014CN00373A (pl)
LT (1) LT2723769T (pl)
MX (2) MX350074B (pl)
PH (1) PH12017501178A1 (pl)
PL (1) PL2723769T5 (pl)
PT (1) PT2723769T (pl)
RU (1) RU2700630C2 (pl)
SG (4) SG194982A1 (pl)
WO (1) WO2012175741A2 (pl)
ZA (1) ZA201309295B (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN108663504B (zh) * 2011-06-23 2021-06-22 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
RS55775B2 (sr) 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
EP2987806A3 (en) * 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2815572T3 (es) * 2014-05-16 2021-03-30 Ablynx Nv Dominios variables de inmunoglobulina
ES2900852T3 (es) * 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2974192C (en) * 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
KR102622281B1 (ko) 2015-03-31 2024-01-08 소리소 파마슈티컬스 인크. 폴리펩티드
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
HUE045437T2 (hu) 2015-05-13 2019-12-30 Ablynx Nv TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
PT3294319T (pt) 2015-05-13 2024-07-22 Ablynx Nv Polipéptidos de recrutamento de células t baseados na reatividade do cd3
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
KR20180072819A (ko) 2015-10-30 2018-06-29 아블린쓰 엔.브이. Il-23에 대한 폴리펩티드
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
NO2768984T3 (pl) * 2015-11-12 2018-06-09
EP3374395A1 (en) * 2015-11-12 2018-09-19 Ablynx NV Improved p2x7 receptor binders and polypeptides comprising the same
CA3005061A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
CN108473564B (zh) * 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
AU2016355570B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
EA201891331A1 (ru) 2015-12-04 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
PL3475699T3 (pl) * 2016-06-23 2022-09-26 Ablynx N.V. Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobuliny
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
KR20240076829A (ko) 2016-11-16 2024-05-30 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
BR112019011189A2 (pt) 2016-12-07 2019-10-08 Ablynx Nv domínios variáveis únicos de imunoglobulina que se ligam à albumina sérica melhorada
MX2019008536A (es) 2017-01-17 2019-09-10 Ablynx Nv Aglutinantes de albumina serica mejorados.
MX2019008496A (es) * 2017-01-17 2019-09-18 Ablynx Nv Aglutinantes de albumina serica mejorados.
CN110546506B (zh) 2017-03-31 2023-04-04 埃博灵克斯股份有限公司 改进的免疫原性测定法
PE20200610A1 (es) 2017-05-31 2020-03-10 Boehringer Ingelheim Int Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales
JP2020521804A (ja) 2017-06-02 2020-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｍｐ１３結合免疫グロブリン
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
US11813307B2 (en) 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
BR112019025392A2 (pt) 2017-06-02 2020-07-07 Ablynx N.V. imunoglobulinas de ligação ao agrecano
EP3655436A1 (en) 2017-07-19 2020-05-27 VIB vzw Serum albumin binding agents
JP6708797B2 (ja) 2017-08-23 2020-06-10 本田技研工業株式会社 鞍乗り型車両のエアバッグ装置
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
BR112020022912A2 (pt) * 2018-07-10 2021-02-23 Regeneron Pharmaceuticals, Inc. métodos para mitigar a interferência de alvo de fármaco em um imunoensaio de anticorpo antifármaco (ada)
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
CA3163764A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
KR20220122652A (ko) 2019-12-06 2022-09-02 아블린쓰 엔.브이. TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
CA3163910A1 (en) 2019-12-09 2021-06-17 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
IL295892A (en) 2020-02-25 2022-10-01 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
AU2021350156A1 (en) 2020-09-25 2023-06-08 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4256067A2 (en) 2020-12-04 2023-10-11 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
EP4259663A1 (en) 2020-12-14 2023-10-18 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising single immunoglobulin variable sites targeting GLYPICAN-3 and the T-cell receptor
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
CA3203141A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
AU2022216460A1 (en) 2021-02-05 2023-09-21 Universiteit Gent Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
TW202330596A (zh) 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
AR128593A1 (es) 2022-02-23 2024-05-22 Takeda Pharmaceuticals Co Proteínas de unión condicionalmente biespecíficas
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
TW202415678A (zh) 2022-06-14 2024-04-16 比利時商艾伯霖克斯公司 靶向ｔ細胞受體的免疫球蛋白單可變結構域
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
DE69126281T2 (de) 1990-11-26 1997-10-16 Akzo Nobel Nv Verfahren zur Herstellung von Antikörpern
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2358576T3 (es) 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001289930A1 (en) 2000-09-25 2002-04-08 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20070087331A1 (en) 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20070118199A (ko) 2003-11-04 2007-12-13 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 고지혈증·고알부민혈증 모델 동물
BRPI0513666A (pt) 2004-08-05 2008-05-13 Genentech Inc anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
CA2608873C (en) 2005-05-20 2017-04-25 Ablynx Nv Single domain vhh antibodies against von willebrand factor
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2006129843A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US20090155283A1 (en) 2005-12-01 2009-06-18 Drew Philip D Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
BRPI0619224A2 (pt) 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
RU2008142833A (ru) 2006-03-30 2010-05-10 Новартис АГ (CH) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CN101553505B (zh) * 2006-08-03 2013-07-17 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) * 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2666511A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
WO2008071447A2 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
WO2008101985A2 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US8623361B2 (en) 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
US8940298B2 (en) * 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US7867497B2 (en) * 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2709399C (en) 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) † 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
EP2403873A1 (en) † 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
CN102481373A (zh) 2009-03-27 2012-05-30 葛兰素集团有限公司 药用融合体和缀合物
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
WO2011064382A1 (en) * 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
BR112012014975A2 (pt) † 2009-12-18 2019-09-24 Sanofi Sa novos anticorpos antagonistas e seus fragmentos fab contra gpvi e seus usos
MX352871B (es) 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
TW201144437A (en) * 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
LT3904391T (lt) 2010-03-10 2024-10-10 Genmab A/S Monokloniniai antikūnai prieš c-met
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
AU2011247612A1 (en) 2010-04-30 2012-12-06 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine IL-23
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
EA201391012A1 (ru) * 2011-01-06 2014-01-30 Глэксо Груп Лимитед Лиганды, связывающиеся с рецепторами tgf-бета типа ii
CN103547592A (zh) 2011-03-30 2014-01-29 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN108663504B (zh) 2011-06-23 2021-06-22 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
JP5987057B2 (ja) 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
EP2987806A3 (en) † 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20130316143A1 (en) 2012-05-22 2013-11-28 Owens Corning Intellectual Capital, Llc Laminated foam product and methods for making laminated foam products
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
ES2815572T3 (es) 2014-05-16 2021-03-30 Ablynx Nv Dominios variables de inmunoglobulina
ES2900852T3 (es) 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
NO2768984T3 (pl) 2015-11-12 2018-06-09
CA3005061A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
AU2016355570B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
CN108473564B (zh) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
EP3408299A1 (en) 2016-01-26 2018-12-05 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
BR112019011189A2 (pt) * 2016-12-07 2019-10-08 Ablynx Nv domínios variáveis únicos de imunoglobulina que se ligam à albumina sérica melhorada
MX2019008496A (es) * 2017-01-17 2019-09-18 Ablynx Nv Aglutinantes de albumina serica mejorados.
CN111032695B (zh) * 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
BR112019025392A2 (pt) 2017-06-02 2020-07-07 Ablynx N.V. imunoglobulinas de ligação ao agrecano
US11813307B2 (en) * 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
IL303783A (en) * 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising single immunoglobulin variable sites targeting GLYPICAN-3 and the T-cell receptor

Also Published As

Publication number Publication date
US20180009888A9 (en) 2018-01-11
IL250396A0 (en) 2017-03-30
CN108663504B (zh) 2021-06-22
US20210388062A1 (en) 2021-12-16
CA3141978A1 (en) 2012-12-27
US20170275361A1 (en) 2017-09-28
KR102240318B1 (ko) 2021-04-15
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
BR122017005075A2 (pt) 2019-09-03
US20170275360A1 (en) 2017-09-28
US12006352B2 (en) 2024-06-11
CN104203975B (zh) 2018-05-11
US20200216532A1 (en) 2020-07-09
US20220119497A1 (en) 2022-04-21
SG10201605048XA (en) 2016-07-28
KR20140040779A (ko) 2014-04-03
CN108653728A (zh) 2018-10-16
JP6258199B2 (ja) 2018-01-10
ES2622006T3 (es) 2017-07-05
US20230242620A1 (en) 2023-08-03
MX350074B (es) 2017-08-25
PH12017501178A1 (en) 2018-07-23
KR20180086280A (ko) 2018-07-30
AU2019201606A1 (en) 2019-04-04
US20210388061A1 (en) 2021-12-16
RU2700630C2 (ru) 2019-09-18
RU2014102007A (ru) 2015-11-27
AU2024200309A1 (en) 2024-02-08
CA3142288A1 (en) 2012-12-27
US20220298227A9 (en) 2022-09-22
KR20220114104A (ko) 2022-08-17
CN108659120A (zh) 2018-10-16
CA2837998C (en) 2022-03-01
IN2014CN00373A (pl) 2015-04-03
IL293163A (en) 2022-07-01
AU2019201606B2 (en) 2021-04-01
US20180355031A1 (en) 2018-12-13
AU2018202782B2 (en) 2020-07-16
AU2017204339A1 (en) 2017-07-13
BR112013032145A8 (pt) 2018-07-03
PL2723769T3 (pl) 2017-07-31
JP2024050769A (ja) 2024-04-10
MX2018007826A (es) 2021-12-08
AU2018202782A1 (en) 2018-05-10
DK2723769T3 (en) 2017-04-03
RU2019128430A (ru) 2019-10-25
KR20240033183A (ko) 2024-03-12
JP2018162305A (ja) 2018-10-18
ZA201309295B (en) 2015-01-28
JP2021107426A (ja) 2021-07-29
SG194982A1 (en) 2013-12-30
KR101965462B1 (ko) 2019-04-04
KR102025035B1 (ko) 2019-11-04
PT2723769T (pt) 2017-04-04
KR20210047369A (ko) 2021-04-29
SG10201707604SA (en) 2017-11-29
JP6869923B2 (ja) 2021-05-12
JP2014520134A (ja) 2014-08-21
MX2013014614A (es) 2014-08-01
AU2012273929B2 (en) 2017-04-27
AU2020230299B2 (en) 2022-10-06
IL229503B (en) 2022-06-01
IL250396B (en) 2022-06-01
BR112013032145A2 (pt) 2017-12-05
CN108659121A (zh) 2018-10-16
BR112013032145B1 (pt) 2022-09-20
WO2012175741A2 (en) 2012-12-27
US20210403536A1 (en) 2021-12-30
DK2723769T4 (da) 2022-09-05
US11192937B2 (en) 2021-12-07
BR122018012485B1 (pt) 2022-09-20
EP2723769B2 (en) 2022-06-15
KR20190107200A (ko) 2019-09-18
US10858418B2 (en) 2020-12-08
SG10201805064SA (en) 2018-07-30
WO2012175741A3 (en) 2013-02-14
KR20190041513A (ko) 2019-04-22
NZ716279A (en) 2017-07-28
EP2723769B1 (en) 2017-01-11
EP2723769A2 (en) 2014-04-30
CA2837998A1 (en) 2012-12-27
CN108653728B (zh) 2022-11-18
JP6982400B2 (ja) 2021-12-17
ES2622006T5 (es) 2022-10-13
AU2020230299A1 (en) 2020-10-01
US11192938B2 (en) 2021-12-07
JP2017160230A (ja) 2017-09-14
NZ617995A (en) 2016-06-24
JP2022031790A (ja) 2022-02-22
HUE031828T2 (en) 2017-08-28
CN104203975A (zh) 2014-12-10
AU2021201506A1 (en) 2021-03-25
KR102246924B1 (ko) 2021-04-30
KR102430693B1 (ko) 2022-08-08
US20200325221A1 (en) 2020-10-15
LT2723769T (lt) 2017-04-10
BR122017005075B1 (pt) 2022-09-20
IL229503A0 (en) 2014-01-30
US20140199295A1 (en) 2014-07-17
CN108663504A (zh) 2018-10-16
IL293155A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
IL250396A0 (en) Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
HK1256304A1 (zh) 用於生成單克隆抗體的方法和試劑
RS55775B1 (sr) Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
HK1200493A1 (en) Anti-b7-h4 antibodies and their uses b7-h4
HUE051068T2 (hu) Interleukin-31 monoklonális ellenanyag
EP2733982A4 (en) CELL MEASUREMENT METHOD, CELL RESOURCE SHARING METHOD, AND CORRESPONDING DEVICE
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
HK1190341A1 (zh) 脫敏血清結合領域和其擴展血清半衰期的用途
PL2673641T3 (pl) Wyrób i sposób testu immunologicznego o podwójnej ścieżce i zredukowanym etapie
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
EP2593475A4 (en) ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
SI2564202T1 (sl) Metode za odkrivanje protiteles proti zdravilu
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
EP2759551A4 (en) ANTIBODIES AGAINST THE AFFINITY COMPLEX
SG11201402709WA (en) Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes
EP2536817A4 (en) IMMUNOASSAY DEVICES FOR THE DETECTION OF ANTIBODIES AND ANTIGENES
EP2599865A4 (en) MONOCLONAL ANTI-FDP ANTIBODY, FDP MEASUREMENT REAGENT, REAGENT KIT CONTAINING SAID ANTIBODY, AND FDP MEASUREMENT METHOD THEREOF
HK1215174A1 (zh) 針對活化蛋白 的人源化單克隆抗體及其用途
EP2669296A4 (en) ANTI-IL28B ANTIBODIES AND METHOD FOR TESTING FOR IL28B THEREOF
EP2751556A4 (en) DEVICE AND METHOD FOR DETECTION AND QUANTIFICATION OF IMMUNOLOGICAL PROTEINS, PATHOGENIC AND MICROBIAL AGENTS AND CELLS